COMMUNIQUÉS West-GlobeNewswire

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43 rd Annual J.P. Morgan Healthcare [...]
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
02/01/2025
WAYNE, Pa. and ROCKVILLE, Md., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced the [...]
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference
02/01/2025
SAN FRANCISCO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025
02/01/2025
AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) [...]
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
02/01/2025
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in [...]
BioStem Technologies CEO to Present at Biotech Showcase 2025
02/01/2025
Presentation to be webcast at 2:30 PM PT on Monday, January 13, 2025 POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, [...]
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity
02/01/2025
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its [...]
The Ensign Group Closes on Expansion in Tennessee, Adds Its First Operation in Alabama
02/01/2025
SAN JUAN CAPISTRANO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]
Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.
02/01/2025
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN [...]
HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy
02/01/2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the [...]
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
01/01/2025
— HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds to advance HUTCHMED’s [...]
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
31/12/2024
Provides financial flexibility by reducing near-term debt maturities, deferring principal redemption payment, and reducing near-term cash needs SAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq [...]
Stem Health Plus Revolutionizes Skin Regeneration with Advanced Stem Cell Skin Graft Technology
31/12/2024
Innovative Solutions Transform Treatment for Burn Victims, Chronic Wounds, and Scar Reduction CHICAGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Stem Health Plus , a leader in regenerative medicine, is introducing [...]
SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder
31/12/2024
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders [...]
Firefly Neuroscience Closes on Financing of up to $12.4 Million
31/12/2024
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain [...]
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
31/12/2024
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great versatility of Altamira’s platform for extrahepatic RNA delivery Circular mRNA significantly increasing protein expression vs. linear mRNA [...]
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
31/12/2024
MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Vireo Growth Inc. Announces Closing of Oversubscribed US$81 Million Equity Securities Offering
31/12/2024
– Oversubscribed equity raise at US$0.625 per share capitalizes Company with a strong balance sheet– – Financing enables Vireo to fund investments in additional organic and acquisitive growth opportunities – MINNEAPOLIS [...]
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
31/12/2024
Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuations Enrollment to be extended due to low influenza infection among challenged participants [...]

Pages